A New Zealand study found the combination of glecaprevir, an NS3/4A protease inhibitor, and Mavyret, or pibrentasvir, an NS5A inhibitor, safe and effective in patients with chronic kidney disease and hepatitis C. Sustained virologic response was seen in 98% of patients, according to findings in The New England Journal of Medicine.
HCV patients with kidney disease respond to combo drug
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.